Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs and the Department of Electronics, Information and Bioengineering (DEIB) of Politecnico di Milano (POLIMI), a world-class scientific institution engaged in cutting-edge research, training and technology transfer, announced the signing of a research contract and the initiation of a project to bear on the challenging problem of identifying specific cells in complex tissues through designing, training and deployment of a deep learning model able to detect them.

Prof. Giacomo Boracchi of the DEIB will lead the research bringing his expertise in image processing and machine learning. In particular, the approach will aim to recognize clinically relevant cells of specific types in darkfield images of lung tissue acquired from the Ikoniscope20. Segmentation of single cell nuclei is a frequent challenge of microscopy image processing, often being the first step of many quantitative data analysis pipelines.

The ongoing collaboration will allow Ikonisys to further enhance its advanced image analysis capabilities and to accelerate the development of the Ikoniscope AI project with the implementation of deep learning models and novel state-of-art techniques into the instrument’s workflow, leading to the development of new applications or enhancement of the existing ones, especially in the most challenging fields such as Circulating Tumor Cells.

Please find the full press release on the investors website.

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

Ikonisys Alessandro Mauri CFO investors@ikonisys.com

NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92

Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mai 2022 à Juin 2022 Plus de graphiques de la Bourse Ikonisys
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Juin 2021 à Juin 2022 Plus de graphiques de la Bourse Ikonisys